Browsing by author "Yarnold, John"
Now showing items 1-20 of 32
-
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Pan, H; Gray, R; Braybrooke, J; Davies, C; Taylor, C; et al. (MASSACHUSETTS MEDICAL SOC, 2017-11-09)BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such ... -
A multicentre study of the evidence for customized margins in photon breast boost radiotherapy.
Harris, EJ; Mukesh, MB; Donovan, EM; Kirby, AM; Haviland, JS; et al. (BRITISH INST RADIOLOGY, 2016-01-01)OBJECTIVE: To determine if subsets of patients may benefit from smaller or larger margins when using laser setup and bony anatomy verification of breast tumour bed (TB) boost radiotherapy (RT). METHODS: Verification imaging ... -
Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Brunt, AM; Wheatley, D; Yarnold, J; Somaiah, N; Kelly, S; et al. (ELSEVIER IRELAND LTD, 2016-07-15)BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin ... -
Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial.
Bhattacharya, IS; Haviland, JS; Hopwood, P; Coles, CE; Yarnold, JR; et al. (ELSEVIER IRELAND LTD, 2019-05)BACKGROUND: In an era of low local relapse rates after adjuvant breast radiotherapy, risks of late normal-tissue effects (NTE) need to be balanced against risk of relapse. NTE are assessed using patient-reported outcome ... -
Changes in radiotherapy fractionation-breast cancer.
Yarnold, J (BRITISH INST RADIOLOGY, 2018-01-18)Conventional fractionation for half a century has been justified on the basis that 2.0 Gy fractions spare dose-limiting late-responding normal tissues to a greater degree than cancerous tissues. Early indications that ... -
Correlation between DNA damage responses of skin to a test dose of radiation and late adverse effects of earlier breast radiotherapy.
Somaiah, N; Chua, MLK; Bourne, S; Daley, F; A' Hern, R; et al. (ELSEVIER IRELAND LTD, 2016-05-15)AIM: To correlate residual double strand breaks (DSB) 24h after 4Gy test doses to skin in vivo and to lymphocytes in vitro with adverse effects of earlier breast radiotherapy (RT). PATIENTS AND METHODS: Patients given whole ... -
Correlation between the radiation responses of fibroblasts cultured from individual patients and the risk of late reaction after breast radiotherapy.
Nuta, O; Somaiah, N; Boyle, S; Chua, MLK; Gothard, L; et al. (ELSEVIER IRELAND LTD, 2016-05-01)Late normal tissue toxicity varies widely between patients and limits breast radiotherapy dose. Here we aimed to determine its relationship to DNA damage responses of fibroblast cultures from individual patients. Thirty-five ... -
Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis.
Glynn, D; Bliss, J; Brunt, AM; Coles, CE; Wheatley, D; et al. (SPRINGER, 2022-11-17)PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) ... -
Do Patient-reported Outcome Measures Agree with Clinical and Photographic Assessments of Normal Tissue Effects after Breast Radiotherapy? The Experience of the Standardisation of Breast Radiotherapy (START) Trials in Early Breast Cancer.
Haviland, JS; Hopwood, P; Mills, J; Sydenham, M; Bliss, JM; et al. (ELSEVIER SCIENCE LONDON, 2016-06-01)AIMS: In radiotherapy trials, normal tissue effects (NTE) are important end points and it is pertinent to ask whether patient-reported outcome measures (PROMs) could replace clinical and/or photographic assessments. Data ... -
Evaluation of the START (standardisation of breast radiotherapy) trial
Haviland, J; Bliss, J; Sydenham, M; Cruickshank, C; Yarnold, J (ELSEVIER SCIENCE INC, 2003-06-01) -
FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment.
Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; et al. (SPRINGER, 2018-08-01)BACKGROUND: Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ... -
Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.
Brunt, AM; Haviland, JS; Kirby, AM; Somaiah, N; Wheatley, DA; et al. (ELSEVIER SCIENCE LONDON, 2021-06-10)INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the ... -
From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy.
Yarnold, JR; Brunt, AM; Chatterjee, S; Somaiah, N; Kirby, AM (ELSEVIER SCIENCE LONDON, 2022-05-01)There is a sound empirical basis for hypofractionation in radiotherapy for breast cancer. This article reviews the radiobiological implications of hypofractionation in breast cancer derived from a series of clinical trials ... -
How Low Can You Go? The Radiobiology of Hypofractionation.
Brand, DH; Kirby, AM; Yarnold, JR; Somaiah, N (ELSEVIER SCIENCE LONDON, 2022-05-01)Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) ... -
Hyperbaric oxygen for patients with chronic bowel dysfunction after pelvic radiotherapy (HOT2): a randomised, double-blind, sham-controlled phase 3 trial.
Glover, M; Smerdon, GR; Andreyev, HJ; Benton, BE; Bothma, P; et al. (ELSEVIER SCIENCE INC, 2016-02-01)BACKGROUND: Hyperbaric oxygen has been used as a therapy for patients experiencing chronic intestinal syndromes after pelvic radiotherapy for decades, yet the evidence to support the use of this therapy is based almost ... -
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; et al. (ELSEVIER SCIENCE INC, 2020-05-23)BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard ... -
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), (ELSEVIER SCIENCE INC, 2019-04-06)BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, ... -
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen, CN; Rosenstein, BS; Kerns, SL; Ostrer, H; De Ruysscher, D; et al. (ELSEVIER IRELAND LTD, 2016-12-01)PURPOSE: Several small studies have indicated that the ATM rs1801516 SNP is associated with risk of normal tissue toxicity after radiotherapy. However, the findings have not been consistent. In order to test this SNP in a ... -
Intratumoral Hydrogen Peroxide With Radiation Therapy in Locally Advanced Breast Cancer: Results From a Phase 1 Clinical Trial.
Nimalasena, S; Gothard, L; Anbalagan, S; Allen, S; Sinnett, V; et al. (ELSEVIER SCIENCE INC, 2020-11-15)PURPOSE: Hydrogen peroxide (H2O2) plays a vital role in normal cellular processes but at supraphysiological concentrations causes oxidative stress and cytotoxicity, a property that is potentially exploitable for the treatment ... -
It's PRIMETIME. Postoperative Avoidance of Radiotherapy: Biomarker Selection of Women at Very Low Risk of Local Recurrence.
Kirwan, CC; Coles, CE; Bliss, J; PRIMETIME Protocol Working Group; PRIMETIME Protocol Working Group (2016-09)